Clarivate (CLVT)
Provides data, analytics, workflow tools, and expert services for research and intellectual-property customers.
Something off on this page? Send us feedback.
Sells data, analytics, workflow solutions, and expert services to academia, government, and intellectual-property customers. Its portfolio was built through a carve-out and acquisitions, while the agreed sale of Life Sciences & Healthcare would concentrate it on the other two markets.
Data, analytics, workflow solutions, and expert services support Academia & Government, Intellectual Property, and Life Sciences & Healthcare. The portfolio includes inherited brands such as Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor, and Techstreet, while ProQuest broadened the academic software, content, data, and analytics offering.
Created from Thomson Reuters’ Intellectual Property & Science business, the business expanded through acquisitions including Decision Resources Group, CPA Global, and ProQuest. Its public-market route was a merger with Churchill Capital Corp rather than a conventional operating-company IPO. A July 2026 agreement to sell Life Sciences & Healthcare is intended to focus operations on Academia & Government and Intellectual Property, subject to closing conditions.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 30, 2026 | Barclays | Reiterate | Rating: —Target: $2.50 | Target: $2 |
| Jul 7, 2026 | Barclays | Reiterate | Rating: —Target: — | Target: $2.50 |
| Jan 8, 2026 | Goldman Sachs | Downgrade | Target: $4.20 | Target: $3.60 |
| Dec 17, 2025 | Morgan Stanley | Downgrade | Target: $12 | Target: $3 |
| Oct 30, 2025 | Goldman Sachs | Target | Target: $20 | Target: $4.20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $217.7M · Total debt $4.26B · Total assets $10.49B · Shareholders' equity $4.54B
- Revenue
- $587.3M
- Operating income
- −$200.2M
- Net income
- −$268.6M
No dividends on record.
| Institutions | 92.14% | 589.36M shares | |
|---|---|---|---|
| 248 holders · as of Jun 30, 2026 | |||
| Insiders | 8.57% | 54.84M shares | |
| 19 holders · as of Aug 18, 2026 | |||
| Strategic holders | 6.70% | 42.86M shares | |
| 1 holder · as of Feb 10, 2022 | |||
| Adds to | 107.41% | ||
639.66M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 107.41%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Leonard Green & Partners, L.P.Institution | 18.24% | 116.67M | as of Jun 30, 2026 |
Exor N.V.Institution | 10.52% | 67.29M | as of Jun 30, 2026 |
Clarkston Capital Partners, LLCInstitution | 7.15% | 45.73M | as of Jun 30, 2026 |
Onex Corp1Strategic10 percent owner | 6.70% | 42.86M | filed Feb 10, 2022 |
Generation Investment Management LLPInstitution | 5.17% | 33.07M | filed Jan 24, 2022 |
- Onex Corp's own ownership statement (13G/A, Feb 10, 2022) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Kenneth L. Cornick | director | +250,000 | $1.85 |
| Aug 6, 2026 | Kenneth L. Cornick | director | +650,000 | $1.86 |
| Aug 3, 2026 | Andrew Miles Snyder | director | −2,489,618 | $1.94 |
| Dec 1, 2025 | Bar Veinstein | officer: President, A&G | −309,902 | $3.74 |
| Nov 10, 2025 | Kenneth L. Cornick | director | +100,000 | $3.45 |
- RELX (ADR)
Scientific research analytics and patent-search overlap
- Wiley Class A
Research publishing and digital research solutions overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Clarivate | $1.88 | −2.85% | $1.23B | — | 2.6 | 0.5 | −5.5% |
| RELX (ADR) | $32.97 | −1.32% | $58.33B | 20.2 | — | 4.5 | +1.0% |
| Wiley Class A | $47.50 | +0.44% | $2.48B | 12.7 | — | 1.5 | −2.6% |
| Median | 16.5 | — | 3.0 | −0.8% |